Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 609 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AMG 609 | EXPERIMENTAL | Up to 7 cohorts ranging by various dose levels. |
| Placebo | EXPERIMENTAL | Participants will receive the matching placebo. |
| Name | Type | Description |
|---|---|---|
| AMG 609 | DRUG | Single dose of AMG 609 administered as a subcutaneous injection. |
| Placebo | DRUG | Single dose of placebo administered as a subcutaneous injection. |
* Inclusion Criteria * Men and women age ≥ 18 to ≤ 70 years of age at the time of signing the informed consent * Body mass index (BMI) of ≥ 27 kg/m2 to ≤ 45.0 kg/m2 * Liver steatosis, measured by MRI-PDFF, greater than 8% * Exclusion Criteria * Evidence of other liver disease (eg, viral he...
AMG 609 is an investigational small molecule being developed for the treatment of Non-alcoholic Fatty Liver Disease (NAFLD). It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in patients with NAFLD to evaluate its safety and tolerability.
AMG 609 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 1 clinical development for Non-alcoholic Fatty Liver Disease.
AMG 609 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 trial of AMG 609 in participants with Non-alcoholic Fatty Liver Disease has been completed.
AMG 609 has one completed clinical trial, NCT04857606, titled 'Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease.' This Phase 1 study enrolled 47 participants in the United States and evaluated the drug in patients with NAFLD.
AMG 609 is the investigational name for this drug candidate developed by Amgen. No alternative names have been reported for this compound. It is being studied under the clinical trial identifier NCT04857606 for Non-alcoholic Fatty Liver Disease.